Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma Inc. (COCP) provides this comprehensive news resource for tracking developments in its antiviral therapeutics pipeline. Access official press releases and verified updates on clinical trials, regulatory milestones, and strategic partnerships.
This page serves investors and industry observers seeking timely information about COCP's structure-based drug discovery platform and pipeline progress. Find updates on hepatitis C inhibitors, broad-spectrum influenza treatments, and norovirus antiviral candidates currently in development.
Content includes FDA correspondence, intellectual property filings, preclinical study results, and collaboration announcements with pharmaceutical partners. All materials are sourced directly from company disclosures to ensure regulatory compliance and factual accuracy.
Bookmark this page for consolidated access to Cocrystal Pharma's latest scientific advancements and business developments. Check regularly for updates on their mission to address unmet needs in viral disease treatment through innovative small-molecule therapeutics.
Cocrystal Pharma, Inc. (COCP) announced preliminary results from its Phase 1 study of CC-42344, an oral antiviral targeting influenza A. The study, involving 56 healthy participants, demonstrated a favorable safety and pharmacokinetic profile with promising oral bioavailability and dose-dependent plasma exposures. CC-42344 is designed to address pandemic and seasonal influenza strains, aiming to be a best-in-class treatment option. Full results are expected later in 2022, affirming Cocrystal's commitment to advancing antiviral therapies.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has commenced enrollment in a Phase 1 trial for CC-42344, an orally administered antiviral for influenza A. The company plans to initiate two additional Phase 1 trials in 2022 for COVID-19 antiviral candidates. Notably, Cocrystal reported no revenues for 2021, down from $2 million in 2020, and a net loss of $14.2 million, or $0.16 per share. However, cash reserves increased to $58.7 million, up from $33 million year-over-year, providing sufficient funds for operations through 2023.
Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the 2022 Virtual Growth Conference hosted by Maxim Group and M-Vest from March 28-30, 2022. Interested attendees can register online. A pre-recorded presentation will be accessible for 72 hours starting March 28 at 9:00 a.m. ET. Cocrystal Pharma is focused on developing antiviral therapeutics targeting influenza, coronaviruses, hepatitis C, and noroviruses, utilizing advanced technologies and expertise.
Cocrystal Pharma has initiated dosing in a Phase 1 clinical trial for its antiviral drug CC-42344, targeting both pandemic and seasonal influenza A. Conducted in Australia, this study will assess the drug's safety and pharmacokinetics in 56 healthy adults. CC-42344 is designed to inhibit influenza viral replication and potentially act against drug-resistant strains. Results are expected later this year, marking a key step in Cocrystal's development of innovative antiviral therapies.
Cocrystal Pharma (Nasdaq: COCP) announces participation in two investment conferences. The Q1 Investor Summit on March 8-9 will feature a presentation on March 9 at 11:45 a.m. Eastern time. Additionally, the company will attend the 34th Annual Roth Conference from March 13-15 in California. Cocrystal plans to start enrollment for a Phase 1 trial of influenza A and initiate studies on two SARS-CoV-2 antivirals for COVID-19 treatments. The company emphasizes its strong financial position to support these developments.
Cocrystal Pharma (Nasdaq: COCP) announced the selection of two investigational oral antiviral candidates, CDI-988 and CDI-873, for the treatment of SARS-CoV-2, showing superior in vitro potency against the virus and its variants, including Omicron.
Both candidates are poised for first-in-human trials in 2022, leveraging Cocrystal's proprietary drug discovery platform. The company also plans to expedite the development of an inhalation candidate, CDI-45205. Positive preclinical results and FDA guidance for CDI-45205 support upcoming clinical study plans.
Cocrystal Pharma (Nasdaq: COCP) announced receiving FDA guidance for the development of CDI-45205, a novel SARS-CoV-2 protease inhibitor, as a potential COVID-19 treatment. The FDA's response, which followed a pre-IND briefing, provides insights necessary for advancing the clinical development, including plans for a Phase 1 study set to begin in 2022. Cocrystal aims to conduct formulation development and IND-enabling studies, emphasizing the compound's antiviral efficacy against various SARS-CoV-2 variants, including Omicron.
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A webcast of the presentation will be available on January 10, 2022, at 7:00 a.m. ET. The company aims to initiate first-in-human studies for two SARS-CoV-2 antivirals targeting COVID-19 and is progressing with its influenza A Phase 1 trial. Cocrystal is well positioned financially with a solid cash position and a debt-free balance sheet, allowing it to advance its clinical plans.
Cocrystal Pharma (Nasdaq: COCP) announced significant progress in combating COVID-19, confirming its protease inhibitors' efficacy against the Omicron variant and other strains. The company plans to initiate Phase 1 clinical studies for its intranasal and oral COVID-19 protease inhibitors, CDI-45205 and another yet-to-be-named oral inhibitor, shortly. Their inhibitors have exhibited broad-spectrum activity and promising safety profiles in preclinical studies, displaying no cytotoxicity and good bioavailability.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that President and interim CEO Sam Lee and CFO James Martin will present a company overview during the Noble Capital Markets Virtual Roadshow on December 8, 2021. The presentation will discuss Cocrystal's progress towards initiating clinical studies in 2022 for two COVID-19 protease inhibitors, which have shown broad-spectrum activity against variants including Delta. The company awaits FDA feedback on its IND briefing for its intranasal COVID-19 inhibitor and plans to submit another for its oral inhibitor in early 2022.